These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1589133)

  • 1. [Chemotherapy and thymostimulin in the treatment of advanced-stage breast neoplasms].
    Negri L; Calabrese F; Correggia F; Miozzo S; Giacomasso S
    Minerva Med; 1992 May; 83(5):283-8. PubMed ID: 1589133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of thymic extract 'thymostimulin' on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer.
    Iaffaioli RV; Frasci G; Tortora G; Ciardiello F; Nuzzo F; Scala S; Pacelli R; Bianco AR
    Thymus; 1988-1989; 12(2):69-75. PubMed ID: 3150630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of a controlled clinical protocol in the treatment of patients with operable breast carcinoma with positive axillary lymph nodes. Comparison of a chemotherapeutic regimen with a chemo-immunotherapeutic regimen].
    Mantovani G; Coiana A; Zucca MV; Sanna GP; Floris C; Sulis E; Del Giacco GS
    Recenti Prog Med; 1988 Dec; 79(12):513-8. PubMed ID: 3241904
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
    Neoplasma; 1985; 32(3):381-7. PubMed ID: 2862594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
    Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
    Bellon JR; Shulman LN; Come SE; Li X; Gelman RS; Silver BJ; Harris JR; Recht A
    Cancer; 2004 Apr; 100(7):1358-64. PubMed ID: 15042668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
    Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
    Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
    Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer].
    Gottwald G; Szakolczai I
    Orv Hetil; 1983 Jan; 124(2):79-84. PubMed ID: 6687491
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer 1984: state of the art.
    Sledge GW
    Indiana Med; 1984 Dec; 77(12):935-9. PubMed ID: 6394645
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radio-chemotherapy integration].
    Boidi Trotti A
    Minerva Ginecol; 1985 Jun; 37(6):281-2. PubMed ID: 3839916
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.